Clinical Updates in Non-Small Cell Lung Cancer
Creelan BC. Cancer Control. 2014;21(1):80-89
Sharon E, et al. Chin J Cancer. 2014;33(9):434-444.
Nguyen KS, et al. World J Clin Oncol. 2014;5(4):576-587.
Herbst RS, et al. Nature. 2014;515(7528):563-567.
A Phase I open-label study to evaluate the safety and tolerability of MEDI4736, an anti-programmed cell death-ligand 1(PD-L1) antibody, in combination with tremelimumab in patients with advanced Non-small cell lung cancer.
Antonia S, et al. Ann Oncol. 2014;25(suppl 4; abstr 1327P).
Efficacy and safety of ceritinib in patients (pts) with advanced anaplastic lymphoma kinase (ALK)-rearranged (ALK+) non-small cell lung cancer (NSCLC): An Update of ASCEND-1
Felip E, et al. Ann Oncol. 2014;25(suppl 4; abstr 1295P).
Safety and activity of alectinib against systemic disease and brain metastases in patients with crizotinib-resistant ALK-rearranged non-small-cell lung cancer (AF-002JG): results from the dose-finding portion of a phase 1/2 study
Gadgeel S, et al. Lancet. 2014;15(10):1119-1128.
Interim phase 2 results of study CO-1686-008: A phase 1/2 study of the irreversible, mutant selective, EGFR inhibitor rociletinib (CO-1686) in patients with advanced non small cell lung cancer
Soria J-C, et al. Euro J Cancer. 2014;50(suppl 6):199.
Updated safety and efficacy from a phase I study of AZD9291 in patients (pts) with EGFR-TKI-resistant non-small cell lung cancer (NSCLC).
Yang JC, et al. Ann Oncol. 2014;25(suppl 4; abstr 449PD).
Clinical Updates in Non-Small Cell Lung Cancer (NSCLC)
Roy S. Herbst, MD, PhD; Roman Perez-Soler, MD; Gregory J. Riely, MD, PhD
New Management Strategies to Improve Patient Outcomes